JBPOS-0101 is under clinical development by Bio-Pharm Solutions and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JBPOS-0101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JBPOS-0101 overview

JBPOS-0101 is under development for the treatment of status epilepticus, Parkinson's disease, lennox-gastaut syndrome, dravet syndrome (severe myoclonic epilepsy of infancy), post partum depression (maternal depression / postnatal depression) and ictal spikes, focal epilepsy and Alzheimer's disease. The drug candidate is a phenyl alkyl carbamate compound and acts by targeting metabotropic glutamate receptors 1, 4 and 7. It is administered through oral and intravenous route.

It was under development for the treatment of infantile spasm reduced spasms.

Bio-Pharm Solutions overview

Bio-Pharm Solutions is a novel medication development company concentrating on central nervous system and rare illness treatments. The company is headquartered in Yeongtong, Gyeonggi, South Korea.

For a complete picture of JBPOS-0101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.